Compare PSN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | KYMR |
|---|---|---|
| Founded | 1944 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.4B |
| IPO Year | 2019 | 2020 |
| Metric | PSN | KYMR |
|---|---|---|
| Price | $72.46 | $69.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | $85.08 | ★ $105.35 |
| AVG Volume (30 Days) | ★ 1.1M | 743.7K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.02 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $6,494,748,000.00 | $43,735,000.00 |
| Revenue This Year | N/A | $18.70 |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $33.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.56 | $19.45 |
| 52 Week High | $97.91 | $103.00 |
| Indicator | PSN | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 39.39 |
| Support Level | $68.91 | $71.46 |
| Resistance Level | $70.98 | $76.71 |
| Average True Range (ATR) | 1.81 | 3.72 |
| MACD | 1.52 | -1.19 |
| Stochastic Oscillator | 96.01 | 4.32 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.